ANX7, a candidate tumor suppressor gene for prostate cancer. 2001

M Srivastava, and L Bubendorf, and V Srikantan, and L Fossom, and L Nolan, and M Glasman, and X Leighton, and W Fehrle, and S Pittaluga, and M Raffeld, and P Koivisto, and N Willi, and T C Gasser, and J Kononen, and G Sauter, and O P Kallioniemi, and S Srivastava, and H B Pollard
Departments of Anatomy, Physiology, and Genetics, and Institute for Molecular Medicine, Uniformed Services University School of Medicine, Bethesda, MD 20814, USA. msrivastava@usuhs.mil

The ANX7 gene is located on human chromosome 10q21, a site long hypothesized to harbor a tumor suppressor gene(s) (TSG) associated with prostate and other cancers. To test whether ANX7 might be a candidate TSG, we examined the ANX7-dependent suppression of human tumor cell growth, stage-specific ANX7 expression in 301 prostate specimens on a prostate tissue microarray, and loss of heterozygosity (LOH) of microsatellite markers at or near the ANX7 locus. Here we report that human tumor cell proliferation and colony formation are markedly reduced when the wild-type ANX7 gene is transfected into two prostate tumor cell lines, LNCaP and DU145. Consistently, analysis of ANX7 protein expression in human prostate tumor microarrays reveals a significantly higher rate of loss of ANX7 expression in metastatic and local recurrences of hormone refractory prostate cancer as compared with primary tumors (P = 0.0001). Using four microsatellite markers at or near the ANX7 locus, and laser capture microdissected tumor cells, 35% of the 20 primary prostate tumors show LOH. The microsatellite marker closest to the ANX7 locus showed the highest rate of LOH, including one homozygous deletion. We conclude that the ANX7 gene exhibits many biological and genetic properties expected of a TSG and may play a role in prostate cancer progression.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008297 Male Males
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D002879 Chromosomes, Human, Pair 10 A specific pair of GROUP C CHROMOSOMES of the human chromosome classification. Chromosome 10
D005819 Genetic Markers A phenotypically recognizable genetic trait which can be used to identify a genetic locus, a linkage group, or a recombination event. Chromosome Markers,DNA Markers,Markers, DNA,Markers, Genetic,Genetic Marker,Marker, Genetic,Chromosome Marker,DNA Marker,Marker, Chromosome,Marker, DNA,Markers, Chromosome
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016133 Polymerase Chain Reaction In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships. Anchored PCR,Inverse PCR,Nested PCR,PCR,Anchored Polymerase Chain Reaction,Inverse Polymerase Chain Reaction,Nested Polymerase Chain Reaction,PCR, Anchored,PCR, Inverse,PCR, Nested,Polymerase Chain Reactions,Reaction, Polymerase Chain,Reactions, Polymerase Chain
D016147 Genes, Tumor Suppressor Genes that inhibit expression of the tumorigenic phenotype. They are normally involved in holding cellular growth in check. When tumor suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible. Antioncogenes,Cancer Suppressor Genes,Emerogenes,Genes, Cancer Suppressor,Genes, Growth Suppressor,Genes, Metastasis Suppressor,Growth Suppressor Genes,Metastasis Suppressor Genes,Tumor Suppressor Genes,Anti-Oncogenes,Genes, Onco-Suppressor,Oncogenes, Recessive,Tumor Suppressing Genes,Anti Oncogenes,Anti-Oncogene,Antioncogene,Cancer Suppressor Gene,Emerogene,Gene, Cancer Suppressor,Gene, Growth Suppressor,Gene, Metastasis Suppressor,Gene, Onco-Suppressor,Gene, Tumor Suppressing,Gene, Tumor Suppressor,Genes, Onco Suppressor,Genes, Tumor Suppressing,Growth Suppressor Gene,Metastasis Suppressor Gene,Onco-Suppressor Gene,Onco-Suppressor Genes,Oncogene, Recessive,Recessive Oncogene,Recessive Oncogenes,Suppressor Gene, Cancer,Suppressor Gene, Growth,Suppressor Gene, Metastasis,Suppressor Genes, Cancer,Suppressor Genes, Growth,Suppressor Genes, Metastasis,Tumor Suppressing Gene,Tumor Suppressor Gene

Related Publications

M Srivastava, and L Bubendorf, and V Srikantan, and L Fossom, and L Nolan, and M Glasman, and X Leighton, and W Fehrle, and S Pittaluga, and M Raffeld, and P Koivisto, and N Willi, and T C Gasser, and J Kononen, and G Sauter, and O P Kallioniemi, and S Srivastava, and H B Pollard
December 2001, Science (New York, N.Y.),
M Srivastava, and L Bubendorf, and V Srikantan, and L Fossom, and L Nolan, and M Glasman, and X Leighton, and W Fehrle, and S Pittaluga, and M Raffeld, and P Koivisto, and N Willi, and T C Gasser, and J Kononen, and G Sauter, and O P Kallioniemi, and S Srivastava, and H B Pollard
November 2003, Proceedings of the National Academy of Sciences of the United States of America,
M Srivastava, and L Bubendorf, and V Srikantan, and L Fossom, and L Nolan, and M Glasman, and X Leighton, and W Fehrle, and S Pittaluga, and M Raffeld, and P Koivisto, and N Willi, and T C Gasser, and J Kononen, and G Sauter, and O P Kallioniemi, and S Srivastava, and H B Pollard
October 2019, The Prostate,
M Srivastava, and L Bubendorf, and V Srikantan, and L Fossom, and L Nolan, and M Glasman, and X Leighton, and W Fehrle, and S Pittaluga, and M Raffeld, and P Koivisto, and N Willi, and T C Gasser, and J Kononen, and G Sauter, and O P Kallioniemi, and S Srivastava, and H B Pollard
September 2005, Cancer research,
M Srivastava, and L Bubendorf, and V Srikantan, and L Fossom, and L Nolan, and M Glasman, and X Leighton, and W Fehrle, and S Pittaluga, and M Raffeld, and P Koivisto, and N Willi, and T C Gasser, and J Kononen, and G Sauter, and O P Kallioniemi, and S Srivastava, and H B Pollard
October 2004, Cancer research,
M Srivastava, and L Bubendorf, and V Srikantan, and L Fossom, and L Nolan, and M Glasman, and X Leighton, and W Fehrle, and S Pittaluga, and M Raffeld, and P Koivisto, and N Willi, and T C Gasser, and J Kononen, and G Sauter, and O P Kallioniemi, and S Srivastava, and H B Pollard
May 2016, Nihon rinsho. Japanese journal of clinical medicine,
M Srivastava, and L Bubendorf, and V Srikantan, and L Fossom, and L Nolan, and M Glasman, and X Leighton, and W Fehrle, and S Pittaluga, and M Raffeld, and P Koivisto, and N Willi, and T C Gasser, and J Kononen, and G Sauter, and O P Kallioniemi, and S Srivastava, and H B Pollard
October 2002, Proceedings of the National Academy of Sciences of the United States of America,
M Srivastava, and L Bubendorf, and V Srikantan, and L Fossom, and L Nolan, and M Glasman, and X Leighton, and W Fehrle, and S Pittaluga, and M Raffeld, and P Koivisto, and N Willi, and T C Gasser, and J Kononen, and G Sauter, and O P Kallioniemi, and S Srivastava, and H B Pollard
November 2018, Oncology letters,
M Srivastava, and L Bubendorf, and V Srikantan, and L Fossom, and L Nolan, and M Glasman, and X Leighton, and W Fehrle, and S Pittaluga, and M Raffeld, and P Koivisto, and N Willi, and T C Gasser, and J Kononen, and G Sauter, and O P Kallioniemi, and S Srivastava, and H B Pollard
July 2006, Cancer research,
M Srivastava, and L Bubendorf, and V Srikantan, and L Fossom, and L Nolan, and M Glasman, and X Leighton, and W Fehrle, and S Pittaluga, and M Raffeld, and P Koivisto, and N Willi, and T C Gasser, and J Kononen, and G Sauter, and O P Kallioniemi, and S Srivastava, and H B Pollard
July 2013, Pathology oncology research : POR,
Copied contents to your clipboard!